Buspirone for Anxiety: How It Works and What the Evidence Shows
Buspirone is a medication approved by the FDA for anxiety. The label covers the management of anxiety disorders and the short-term relief of the symptoms of anxiety. It builds over weeks rather than working on the spot, so it is not a medication taken in the moment to calm a panicky afternoon.
That combination of an official anxiety approval and a slow build is the first thing worth understanding about it. The rest of this page covers how it is thought to work, what the measured data say about its speed, who it has been tested against, what it does and does not share with benzodiazepines, and the limits that the label itself states.
How buspirone works
The FDA label for buspirone states that the mechanism of action of buspirone is unknown. It is worth taking at face value. Plenty of web pages describe a mechanism as settled fact. The label does not.
What the label does report are findings from preclinical studies. Buspirone has high affinity for serotonin 5-HT1A receptors and moderate affinity for D2 dopamine receptors. It has no significant affinity for benzodiazepine receptors. The label also says it has no anticonvulsant or muscle relaxant effect, and that it lacks the prominent sedative effect of typical anxiolytics.
These are descriptions of where the drug binds in laboratory studies. They are not an explanation of why anxiety improves in people who take it, and the label does not offer one. A reasonable reading is that researchers know which receptors buspirone touches and do not yet know which of those interactions produces the clinical effect.
Why it is not a rescue medication
Buspirone is titrated over days. Per the label, the usual shape is a start at 15 mg a day, given as 7.5 mg twice daily, raised by 5 mg every 2 to 3 days as needed, up to a maximum of 60 mg a day. In the trials, 20 to 30 mg a day in divided doses was common. The drug is dosed two to three times daily, and the effect builds gradually.
The clearest measurement of that speed is a head-to-head comparison from Enkelmann in 1991. Alprazolam improved symptoms within the first week. Buspirone improved them gradually across six weeks. Anyone who has read that buspirone is fast-acting should know that the sentence appears in one meta-analysis as a narrative remark, that onset was not an outcome that analysis measured, and that the measured comparison points the other way.
So a single dose taken because anxiety has spiked is not how buspirone is used. It is a medication whose effect is judged over a stretch of weeks.
Is buspirone a benzodiazepine?
No. Buspirone has no significant affinity for benzodiazepine receptors, which is the label’s own statement, and it lacks the prominent sedative effect of typical anxiolytics. A common question is whether buspirone is basically alprazolam, which is sold as Xanax. The two differ in receptor profile, in speed, and in what the testing has shown about dependence.
Two more differences matter for people who have taken a benzodiazepine before, and both are covered below.
What was tested about dependence
Buspirone is not a controlled substance, according to the label’s section on drug abuse and dependence. The more useful point is that the absence of dependence was tested directly rather than assumed.
- In a direct abuse-liability study, buspirone produced dysphoria rather than euphoria and scored below placebo.
- The label reports that volunteers with a history of recreational drug use could not tell buspirone apart from placebo, and preferred diazepam.
- A six-month trial with blind abrupt discontinuation found no withdrawal reaction.
Tested absence of dependence is a different thing from untested absence. Some medications are described as non-habit-forming because nobody has run the experiment. In buspirone’s case the experiments were run, and that is the part of its record that is best supported.
The Beers Criteria
The American Geriatrics Society publishes the Beers Criteria, a list of medications that carry added risk for adults 65 and older. Buspirone does not appear anywhere in the 2023 update. Benzodiazepines are listed under “avoid”, and so is hydroxyzine, another medication approved for anxiety.
For an older adult comparing anxiety medications, this is a useful fact. It is also a limited one, and it should be read for what it is. Being absent from a caution list says that the Beers panel did not flag buspirone. It is not an endorsement of safety, and it does not replace an individual review of what a person already takes and what else is going on medically. That review is a routine part of geriatric psychiatry.
The limits the label states
The FDA label says that effectiveness in long-term use, meaning use for more than 3 to 4 weeks, has not been demonstrated in controlled trials. That is a direct statement from the manufacturer’s approved labeling, and it sits alongside the approval for anxiety. Both are true at once.
The guideline picture is similarly restrained. Buspirone is absent from the NICE pathway entirely. In guidelines that do list it for generalized anxiety disorder, it is placed second-line, behind the first-line options. For panic disorder and social anxiety, the Canadian guideline goes further and does not recommend it. None of that is a safety finding. It is a judgment about how strong the evidence is.
None of that rules the drug out. It describes how strong the evidence is, which is a different question from whether a particular person responds to it.
Recent benzodiazepine use changes the picture
Buspirone works less well in people who have recently come off a benzodiazepine. This was found in two independent datasets: Chessick in 2006, and DeMartinis in 2000, which included 735 people. Two separate groups reaching the same result makes it more credible than a single finding.
Buspirone also does not cover benzodiazepine withdrawal. In a taper trial from Rickels in 2000, it did not significantly beat placebo. Anyone currently tapering a benzodiazepine should hear from the prescriber who is managing the taper before changing anything.
Side effects, with the real figures
The label pools 17 trials, and the side-effect figures below come from that pool. Each pair shows buspirone first and placebo second.
- Dizziness: 12% on buspirone against 3% on placebo.
- Nausea: 8% against 5%.
- Headache: 6% against 3%.
- Nervousness: 5% against 1%.
About one in ten people in those trials stopped taking buspirone because of a side effect.
Drowsiness, insomnia, dry mouth and fatigue came up at the same rate on placebo as on buspirone in these trials, so they are not listed here as effects of the drug. That matters because drowsiness is the effect many people expect from an anxiety medication, and in the pooled data buspirone did not produce more of it than a sugar pill.
Grapefruit, food, and interacting drugs
Grapefruit juice raised exposure to buspirone 9.2-fold. That is a large change for something that comes from a breakfast drink.
Food in general also changes how much of the drug reaches the bloodstream. Food raises it. For that reason the label says to take buspirone consistently, either always with food or always without. The point of that wording is steadiness from day to day rather than any particular time on the clock.
Two drug interactions carry specific warnings in the label:
- Monoamine oxidase inhibitors (MAOIs) and buspirone should be at least 14 days apart, in either direction.
- Serotonin syndrome is a stated risk with linezolid or intravenous methylene blue.
What an evaluation covers
Whether buspirone suits a given person depends on things a search result cannot show: the diagnosis, any recent benzodiazepine use, age, other medications, what has already been tried, and how a person feels about a medication that builds slowly. A psychiatric evaluation exists to weigh those together.
Getting a buspirone prescription
Buspirone is a prescription medication approved by the FDA for anxiety, and you get it through an evaluation with a licensed prescriber. PsychBright’s psychiatrists prescribe it when an evaluation finds it fits. Evaluations are done by video across California, for adults 18 and older, usually within the same week.
The evaluation looks at a few things that the label and the research make relevant to buspirone. Recent benzodiazepine use is one, because buspirone works less well in people who have recently come off a benzodiazepine, and it does not cover benzodiazepine withdrawal. Other medications are another. Monoamine oxidase inhibitors (MAOIs) and buspirone should be at least 14 days apart, in either direction, and other drugs that act on serotonin are reviewed as well. Grapefruit is also on the list, since in a study in healthy volunteers, large amounts of double-strength grapefruit juice raised exposure to buspirone 9.2-fold.
The evaluation also covers whether a slow-building medication suits the person. Buspirone builds over weeks, so it is a planned treatment and is not taken as needed. Whether it fits is the prescriber’s decision, and no prescription is promised in advance.
Frequently asked questions
Is buspirone basically Xanax?
No. Xanax is the brand name of alprazolam, a benzodiazepine. Buspirone has no significant affinity for benzodiazepine receptors, according to the FDA label. In a head-to-head comparison, alprazolam improved symptoms within the first week while buspirone improved them gradually across six weeks. Buspirone is also not a controlled substance, and testing found no withdrawal reaction after abrupt discontinuation in a six-month trial.
Is buspirone stimulating or sedating?
The label says buspirone lacks the prominent sedative effect of typical anxiolytics. In the label’s pooled trials, drowsiness occurred at the same rate as on placebo. The effects that did occur more often than on placebo were dizziness (12% against 3%), nausea (8% against 5%), headache (6% against 3%) and nervousness (5% against 1%).
What does it feel like when buspirone is working?
The sources behind this page describe the pattern rather than a sensation. Improvement builds gradually over weeks and is judged across that stretch, rather than arriving as a noticeable change soon after a dose. In the head-to-head comparison, buspirone improved symptoms gradually across six weeks.
Why is buspirone not a first choice for anxiety?
Several facts point the same way. The FDA label states that effectiveness beyond 3 to 4 weeks has not been demonstrated in controlled trials. It is absent from the NICE pathway. Guidelines that list it for generalized anxiety disorder place it second-line, and the Canadian guideline does not recommend it for panic disorder or social anxiety. It also works less well in people who have recently come off a benzodiazepine. These describe the strength of the evidence and not a safety concern.
What is a drawback of buspirone?
The main one is speed, since the effect builds over weeks and the drug does not work as a rescue medication. Dizziness was the most common side effect in the label’s pooled trials, at 12% against 3% on placebo, and about one in ten people stopped for a side effect. It also works less well after recent benzodiazepine use and does not cover benzodiazepine withdrawal.
What not to eat with buspirone?
Grapefruit is the notable one. Grapefruit juice raised exposure to buspirone 9.2-fold. Food in general raises how much of the drug reaches the bloodstream, which is why the label calls for consistency, either always with food or always without.
What is the best time to take buspirone?
The label does not name a best time of day. What it does say is to take buspirone consistently, always with food or always without, because food changes how much reaches the bloodstream. The drug is dosed two to three times daily, and the specific schedule is something the prescriber sets.
Is buspirone approved by the FDA for anxiety?
Yes. The label describes it for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. That separates it from medications such as gabapentin and propranolol, which are prescribed for anxiety off-label.
Does buspirone cause dependence?
It was tested rather than assumed. A direct abuse-liability study found it produced dysphoria rather than euphoria and scored below placebo, and a six-month trial with blind abrupt discontinuation found no withdrawal reaction. The label also lists it as not a controlled substance.
Getting a proper assessment
If anxiety is affecting your daily life, the useful next step is an evaluation rather than a decision about a specific medication. PsychBright Health provides psychiatric evaluation and medication management by telehealth across California, usually within the same week.
If you are in crisis, do not wait for an appointment. Call or text 988 for the Suicide and Crisis Lifeline, or call 911 if someone is in immediate danger.